Neurokinin-1 Receptor (NK-1R) Antagonists As a New Strategy to Overcome Cancer Resistance

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 May 14

PMID 35565383

Authors

Marilina Garcia-Aranda

Teresa Tellez

Lauraine McKenna

Maximino Redondo

Affiliations

Soon will be listed here.

Abstract

Nowadays, the identification of new therapeutic targets that allow for the development of treatments, which as monotherapy, or in combination with other existing treatments can contribute to improve response rates, prognosis and survival of oncologic patients, is a priority to optimize healthcare within sustainable health systems. Recent studies have demonstrated the role of Substance P (SP) and its preferred receptor, Neurokinin 1 Receptor (NK-1R), in human cancer and the potential antitumor activity of NK-1R antagonists as an anticancer treatment. In this review, we outline the relevant studies published to date regarding the SP/NK-1R complex as a key player in human cancer and also evaluate if the repurposing of already marketed NK-1R antagonists may be useful in the development of new treatment strategies to overcome cancer resistance.

Citing Articles

Alternative Splicing at the Crossroad of Inflammatory Bowel Diseases and Colitis-Associated Colon Cancer.

Matos P, Jordan P Cancers (Basel). 2025; 17(2).

PMID: 39858001 PMC: 11764256. DOI: 10.3390/cancers17020219.

Glioma and Peptidergic Systems: Oncogenic and Anticancer Peptides.

Sanchez M, Mangas A, Covenas R Int J Mol Sci. 2024; 25(14).

PMID: 39063232 PMC: 11277022. DOI: 10.3390/ijms25147990.

-Derived Santamarine Inhibits Oral Cancer Cell Proliferation via Oxidative Stress-Mediated Apoptosis and DNA Damage.

Lu H, Chen K, Yen C, Chen C, Chien T, Shu C Pharmaceuticals (Basel). 2024; 17(2).

PMID: 38399445 PMC: 10892349. DOI: 10.3390/ph17020230.

Advances in the research and application of neurokinin-1 receptor antagonists.

Hong X, Ma J, Zheng S, Zhao G, Fu C J Zhejiang Univ Sci B. 2024; 25(2):91-105.

PMID: 38303494 PMC: 10835208. DOI: 10.1631/jzus.B2300455.

Neurokinin-2 receptor negatively modulates substance P responses by forming complex with Neurokinin-1 receptor.

Nguyen L, Cho M, Nguyen T, Park H, Nguyen H, Mykhailova K Cell Biosci. 2023; 13(1):212.

PMID: 37968728 PMC: 10652611. DOI: 10.1186/s13578-023-01165-6.

References

Ye Q, Liu K, Shen Q, Li Q, Hao J, Han F . Reversal of Multidrug Resistance in Cancer by Multi-Functional Flavonoids. Front Oncol. 2019; 9:487. PMC: 6581719. DOI: 10.3389/fonc.2019.00487. View

Kakuta N, Tsutsumi Y, Horikawa Y, Kawano H, Kinoshita M, Tanaka K . Neurokinin-1 receptor antagonism, aprepitant, effectively diminishes post-operative nausea and vomiting while increasing analgesic tolerance in laparoscopic gynecological procedures. J Med Invest. 2011; 58(3-4):246-51. DOI: 10.2152/jmi.58.246. View

Munoz M, Rosso M . The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug. Invest New Drugs. 2009; 28(2):187-93. DOI: 10.1007/s10637-009-9218-8. View

Groneberg D, Harrison S, Dinh Q, Geppetti P, Fischer A . Tachykinins in the respiratory tract. Curr Drug Targets. 2006; 7(8):1005-10. DOI: 10.2174/138945006778019318. View

Garcia-Recio S, Gascon P . Biological and Pharmacological Aspects of the NK1-Receptor. Biomed Res Int. 2015; 2015:495704. PMC: 4573218. DOI: 10.1155/2015/495704. View

Matalinska J, Swic A, Lipinski P, Misicka A . Antiproliferative effects of [D-Pro2, D-Trp7,9]-Substance P and aprepitant on several cancer cell lines and their selectivity in comparison to normal cells. Folia Neuropathol. 2020; 58(3):237-244. DOI: 10.5114/fn.2020.100066. View

Bootman M, Chehab T, Bultynck G, Parys J, Rietdorf K . The regulation of autophagy by calcium signals: Do we have a consensus?. Cell Calcium. 2017; 70:32-46. DOI: 10.1016/j.ceca.2017.08.005. View

Garcia-Recio S, Fuster G, Fernandez-Nogueira P, Pastor-Arroyo E, Park S, Mayordomo C . Substance P autocrine signaling contributes to persistent HER2 activation that drives malignant progression and drug resistance in breast cancer. Cancer Res. 2013; 73(21):6424-34. DOI: 10.1158/0008-5472.CAN-12-4573. View

Beirith I, Renz B, Mudusetti S, Ring N, Kolorz J, Koch D . Identification of the Neurokinin-1 Receptor as Targetable Stratification Factor for Drug Repurposing in Pancreatic Cancer. Cancers (Basel). 2021; 13(11). PMC: 8198055. DOI: 10.3390/cancers13112703. View

10.

Goldberg T, Fidler B, Cardinale S . Rolapitant (Varubi): A Substance P/Neurokinin-1 Receptor Antagonist for the Prevention of Chemotherapy-Induced Nausea and Vomiting. P T. 2017; 42(3):168-172. PMC: 5312632. View

11.

Dikmen M, Gokhaner G, Canturk Z . Evaluation of the antileukemic effects of neurokinin-1 receptor antagonists, aprepitant, and L-733,060, in chronic and acute myeloid leukemic cells. Anticancer Drugs. 2019; 30(7):e0769. DOI: 10.1097/CAD.0000000000000769. View

12.

Weinstein I . Cancer. Addiction to oncogenes--the Achilles heal of cancer. Science. 2002; 297(5578):63-4. DOI: 10.1126/science.1073096. View

13.

Aapro M, Carides A, Rapoport B, Schmoll H, Zhang L, Warr D . Aprepitant and fosaprepitant: a 10-year review of efficacy and safety. Oncologist. 2015; 20(4):450-8. PMC: 4391760. DOI: 10.1634/theoncologist.2014-0229. View

14.

Zhang Z, Zhou L, Xie N, Nice E, Zhang T, Cui Y . Overcoming cancer therapeutic bottleneck by drug repurposing. Signal Transduct Target Ther. 2020; 5(1):113. PMC: 7331117. DOI: 10.1038/s41392-020-00213-8. View

15.

Halik P, Kozminski P, Matalinska J, Lipinski P, Misicka A, Gniazdowska E . In Vitro Biological Evaluation of Aprepitant Based Lu-Radioconjugates. Pharmaceutics. 2022; 14(3). PMC: 8949964. DOI: 10.3390/pharmaceutics14030607. View

16.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

17.

Patergnani S, Danese A, Bouhamida E, Aguiari G, Previati M, Pinton P . Various Aspects of Calcium Signaling in the Regulation of Apoptosis, Autophagy, Cell Proliferation, and Cancer. Int J Mol Sci. 2020; 21(21). PMC: 7664196. DOI: 10.3390/ijms21218323. View

18.

Robinson P, Kasembeli M, Bharadwaj U, Engineer N, Eckols K, Tweardy D . Substance P Receptor Signaling Mediates Doxorubicin-Induced Cardiomyocyte Apoptosis and Triple-Negative Breast Cancer Chemoresistance. Biomed Res Int. 2016; 2016:1959270. PMC: 4766315. DOI: 10.1155/2016/1959270. View

19.

Legi A, Rodriguez E, Eckols T, Mistry C, Robinson P . Substance P Antagonism Prevents Chemotherapy-Induced Cardiotoxicity. Cancers (Basel). 2021; 13(7). PMC: 8038801. DOI: 10.3390/cancers13071732. View

20.

Munoz M, Covenas R . Neurokinin-1 receptor antagonists as antitumor drugs in gastrointestinal cancer: A new approach. Saudi J Gastroenterol. 2016; 22(4):260-8. PMC: 4991196. DOI: 10.4103/1319-3767.187601. View